TOWNSHIP, Michigan – (COMMERCIAL THREAD) – MMS Holdings Inc. (MMS) – an award-winning, data-driven CRO – announced the release of SmartStart ™ Technology models to reduce time and effort in the document content creation process while increasing the quality of deliverables.
SmartStart ™ Models apply structured authoring rules to the authoring process and include technology models for protocols, statistical analysis plans (SAP) and clinical study reports (CSR). These models were developed to improve consistency, time savings and quality while allowing data reuse between deliverables, such as protocol to protocol, protocol to CSR, protocol to SAP, CSR to CSR and SAP to SAP.
Main features of SmartStart ™ Models are proven to reduce human error by:
Automatic sharing of reusable content within and between protocols, SAP and CSR
Reusable content in the body of the protocol and the CSR will automatically update in the synopsis
Reusable content can be imported between documents
Improved quality and reduced creation and quality control efforts
Efficient presentation of reusable content across all products, programs and therapeutic areas
Decreased review times, allowing reviewers to focus on newly added content
“One of the goals of the organization is to accelerate the development of new therapies,” said Audelia Munguia, director of security risk management at MMS. “The innovative technology of our SmartStart ™ Templates will dramatically reduce the time and effort required when writing deliverables and get therapies to patients faster. ”
Sponsors who use SmartStart ™ Models will benefit from increased consistency and efficiency for internal teams, sites, regulators, experimental review boards (IRBs) and patients, as well as in downstream documents, as previously completed protocols can be transferred to SmartStart ™ Templates.
MMS Holdings (MMS) is an innovative, data-driven CRO that supports the pharmaceutical, biotech and medical device industries with a proven science-based approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-based services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global presence on four continents, MMS maintains a 97% customer satisfaction rate, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the past three consecutive years.